Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01030042
Other study ID # 2007-006254-26
Secondary ID
Status Completed
Phase Phase 3
First received December 9, 2009
Last updated July 14, 2015
Start date September 2009
Est. completion date June 2015

Study information

Verified date December 2009
Source Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics CommitteeItaly: The Italian Medicines Agency
Study type Interventional

Clinical Trial Summary

Primary Objectives:

Aim of this study is to compare the efficacy and safety of two different sequences of chemotherapeutic agents in order to optimize the treatment of patients with metastatic colorectal cancer progressed to a first line chemotherapy with FOLFIRI and bevacizumab. Primary endpoint will be overall survival, defined as the time elapsed from the date of randomization to the date of patient death due to any cause, or the last date the patient was known to be alive.

Secondary Objectives Progression free survival, Quality of life, Health resource utilisation and economic evaluation, Toxicity and incidence of adverse events

The study regimen includes:

Strategy A: FOLFOX-4 followed, after progression, by irinotecan/cetuximab Strategy B: irinotecan/cetuximab followed, after progression, by FOLFOX-4 Patients will be randomly assigned to one of the two treatment sequences (with 1:1 ratio) using a block design randomization procedure stratified according to center.

The patient accrual period is planned for approximately 36 months. To assess OS, all pts will be followed for up to 18 months after the last patient is randomised. The maximum estimated study duration is approximately 54 months.All statistical analyses will be based on an intention-to-treat approach. CONSORT rules will be applied to describe study flow and protocol deviations.


Description:

Target population:

Patients with histologically confirmed metastatic colorectal cancer progressed after a first line treatment containing FOLFIRI and BEV

Inclusion criteria:

- Age >18 < 75 years of age

- Diagnosis of histologically proven adenocarcinoma of the colon or rectum, stage IV

- K-ras wild-type

- ECOG performance status 0-1 at study entry

Endpoints:

- Response Rate, Disease control rate, The duration of overall response, Overall survival, PFS, Time to treatment failure, Quality of Life, Incidence of AEs, Frequency and nature of serious adverse reactions (SADRs), Premature withdrawals

Statistical methods:

Assuming a randomization ratio of 1:1, 282 deaths are required in order to achieve a power of 80% of detecting a hazard ratio of 0.72 in favour of one of the two sequences, translating in an increase of median survival time from 10 to 14 months, with a type I error of 5%, two-sided, using the Mantel-Cox version of the log-rank test. With a uniform accrual period of 3 years and a follow-up of 18 months, about 350 patients will be needed to reach the target number of events.

All statistical analyses will be based on an intention-to-treat approach. CONSORT rules will be applied to describe study flow and protocol deviations.

All OS and PFS curves will be drawn with the Kaplan-Meier method. Results will be presented as Hazard Ratio (HRs) and their 95% Confidence Interval (CIs).

On annual basis, starting from the second year, an interim analysis will be conducted. In principle, no formal stopping rule will be applied, unless otherwise suggested by the DSMC. Safety reports will be drawn on annual basis.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date June 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Age >18 <75 years of age

- Diagnosis of histologically proven adenocarcinoma of the colon or rectum, stage IV

- K-ras wild-type

- Performance Status (ECOG-PS) 0-1 at study entry

- Neutrophils = 1.5 x 1039/L, platelets = 100 x 109/L, and hemoglobin = 9 g/dL

- Bilirubin level either normal or < 1.5 x upper limit of normal (ULN)

- Asparagine aminotransferase (ASAT) and alanine aminotransferase (ALAT) = 2.5 X ULN (= 5 x ULN if liver metastasis are present)

- Serum creatinine < 1.5 x ULN

- Effective contraception for both male and female patients

- Life expectancy of = 3 months

- Signed written informed consent

Exclusion Criteria:

- History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications

- Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix)

- History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for oral drug intake

- Known grade 3 or 4 allergic reaction to any of the components of the treatment

- Known drug abuse/ alcohol abuse

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOX-4
Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
Irinotecan/Cetuximab
CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time. IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.

Locations

Country Name City State
Italy A.O. Ospedale Umberto I - Università - Località Torretta Ancona
Italy Ospedali Riuniti, Largo Barozzi, 1 Bergamo
Italy Fondazione Poliambulanza, Via Bissolati 57 Brescia
Italy Spedali Civili Brescia BS
Italy Università degli Studi Candiolo TO
Italy Istituto Oncologico del Mediterraneo Catania CT
Italy A.O. Ospedale S.Anna Como
Italy ASL 11 Empoli FI
Italy Ospedale Profili Fabriano AN
Italy Usl 11 Ospedale Murri Fermo AP
Italy Università Firenze FI
Italy Ospedale Serbelloni Gorgonzola MI
Italy AUSL di Lanciano-Vasto Lanciano CH
Italy Ospedale Mater Salutis Legnago VR
Italy Ospedale Maggiore Lodi LO
Italy A.O. Carlo Poma - Via Albertoni, 1 Mantova
Italy Istituto di Ricerca S.Raffaele Milano MI
Italy Ospedale Fatebenefratelli Milano MI
Italy A.O. S.Gerardo Monza MI
Italy Istituto Tumori - Fondazione Pascale Napoli
Italy Istituto Oncologico Veneto Padova PD
Italy A.O. S.Salvatore Pesaro PS
Italy Azienda Ospedaliera San Carlo Potenza PZ
Italy A.O. S.Giovanni Calabita Fatebenefratelli Roma
Italy Ospedale Sant'Andrea Roma RM
Italy Università Campus Biomedico, Via Emilio Longoni, 83 Roma
Italy Università Policlinico Umberto I Roma RM
Italy AULSS 18 di Rovigo Rovigo RO
Italy Ospedale Morelli Sondalo SO
Italy Ospedale S.Vincenzo Taormina ME
Italy A.O. Treviglio-Caravaggio, P.le Ospedale n1 Treviglio Bergamo
Italy Ospedale Civile Urbino PS

Sponsors (1)

Lead Sponsor Collaborator
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival the time from the date of randomisation to the date of death Yes
Secondary Progression free survival the time relapsed from the date of randomization and the date of progression after third-line treatment or death Yes
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphereâ„¢ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2